Brio Consultants LLC Makes New $230,000 Investment in Johnson & Johnson (NYSE:JNJ)

Brio Consultants LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,296 shares of the company’s stock, valued at approximately $230,000.

A number of other hedge funds also recently bought and sold shares of the stock. Family CFO Inc purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC lifted its holdings in shares of Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $49,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $171.79 on Friday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The company has a market capitalization of $451.67 billion, a P/E ratio of 25.01, a P/E/G ratio of 3.29 and a beta of 0.59. The business’s 50-day moving average is $175.41 and its two-hundred day moving average is $174.52.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same period last year, the firm earned $2.48 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on JNJ shares. UBS Group decreased their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Daiwa Capital Markets started coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. The Goldman Sachs Group raised their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Citigroup reduced their target price on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, Credit Suisse Group raised their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.